Telomir Pharmaceuticals I... (TELO)
NASDAQ: TELO
· Real-Time Price · USD
1.18
-0.02 (-1.67%)
At close: Sep 03, 2025, 3:59 PM
1.16
-1.69%
After-hours: Sep 03, 2025, 07:27 PM EDT
Telomir Pharmaceuticals Common Stock Income Statement
Financials in USD. Fiscal
year is
undefined.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 |
Revenue | n/a | n/a | 18.79M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | 9.4M | 6.01M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | 9.4M | -6.01M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -5.07M | -2.19M | -2.91M | -6.01M | -1.47M | -1.92M | -8.57M | -954.15K | -1.43M | -482.94K | -487.1K | -233.5K | -70.06K | -63.49K |
Interest Income | 1.36K | 7.95K | 7.06K | 15.45K | 25.49K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -5.07M | -2.18M | -2.9M | -5.99M | -1.45M | -6.25M | -9.33M | -1.71M | -1.55M | -482.94K | -487.1K | -233.5K | -70.06K | -63.49K |
Net Income | -5.07M | -2.18M | -2.9M | -5.99M | -1.45M | -6.25M | -9.33M | -1.71M | -1.55M | -482.94K | -487.1K | -233.5K | -70.06K | -63.49K |
Selling & General & Admin | 5.03M | 1.85M | 2.64M | 5.38M | 879.7K | 741.54K | 395.29K | 102.19K | 60.11K | 42.6K | 9.79K | 3.75K | 3.75K | 3.65K |
Research & Development | 42.84K | 337K | 269.08K | 627.43K | 594.8K | 804.02K | 203.78K | 262.56K | 667.63K | 440.33K | 477.31K | 229.75K | 66.31K | 59.84K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 5.07M | 2.19M | 2.91M | 6.01M | 1.47M | 1.92M | 1.08M | 954.15K | 1.43M | 482.94K | 487.1K | 233.5K | 70.06K | 63.49K |
Interest Expense | 1.34K | n/a | n/a | n/a | n/a | 4.34M | 761.82K | 757.17K | 124.05K | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 5.07M | 2.19M | 2.91M | 6.01M | 1.47M | 1.92M | 1.08M | 954.15K | 1.43M | 482.94K | 487.1K | 233.5K | 70.06K | 63.49K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | -1.08M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 30.01M | 29.76M | 29.54M | 29.61M | 29.61M | 27.77M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M |
Shares Outstanding (Diluted) | 30.01M | 29.76M | 29.54M | 29.61M | 29.61M | 27.77M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M | 29.61M |
EPS (Basic) | -0.17 | -0.07 | -0.1 | -0.2 | -0.05 | -0.23 | -0.32 | -0.06 | -0.05 | -0.02 | -0.02 | -0.01 | -0.00 | -0.00 |
EPS (Diluted) | -0.17 | -0.07 | -0.1 | -0.2 | -0.05 | -0.23 | -0.32 | -0.06 | -0.05 | -0.02 | -0.02 | -0.01 | -0.00 | -0.00 |
EBITDA | -5.07M | -2.19M | -2.9M | -5.99M | -1.45M | -1.92M | -8.57M | -954.15K | -1.43M | n/a | n/a | n/a | -70.06K | -63.49K |
EBIT | -5.07M | -2.19M | -2.9M | -5.99M | -1.45M | -1.92M | -8.57M | -954.15K | -1.43M | -482.94K | -487.1K | -233.5K | -70.06K | -63.49K |
Depreciation & Amortization | n/a | 2.19M | -1.96M | 15.45K | 25.49K | 1.92M | 1.08M | 954.15K | 1.43M | 482.94K | 487.1K | 233.5K | n/a | n/a |